Shares of Glenmark slipped 2.16% to ₹2,280.60 on Tuesday, after the company disclosed its outlook for the US segment. The drugmaker projects US revenue to exceed $430 million in FY27, marking a 10–12% rise year‑on‑year, according to CFO Anurag Mantri in the latest financial briefing.
Glenmark is also gearing up its margin profile, targeting 21–22% EBITDA despite heightened input and logistics costs. The company plans to deploy $700 million from its AbbVie licensing agreement into its multi‑specific antibody platform, a move aimed at boosting the share of revenue from innovative drugs.
In parallel, Glenmark is preparing to launch generic GLP‑1 products and expanding its respiratory portfolio. The Monroe manufacturing facility is ramping up capacity to support these new launches, a development highlighted by Chairman Glenn Saldanha during the earnings call.
Market sentiment remains cautious; the stock has declined 6.4% over the past month but has gained 12.6% year‑to‑date. Analysts view the share as a value opportunity if the company can maintain its margin target.
Looking ahead, Glenmark’s next earnings call is scheduled for March 2025, where it will update on pipeline progress and the impact of the AbbVie proceeds on its innovation agenda.